T-cell engager

This page covers all T-cell engager drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CD3.

Targets

CD3

Phase 2 pipeline (1)

• CAN-2409 · Candel Therapeutics, Inc. · Oncology
  CAN-2409 is a T-cell engager that targets the CD3 component of the T-cell receptor.